Live
Lonza NewsLonza Group Ag (OTCMKTS:LZAGY) Short Interest Down 87.6% in March - MarketBeatCytiva (Google News)Yoshindo And Cytiva Strengthen Japan’s Biologics Sovereignty Through Scalable Modular Manufacturing - BioPharma APACWatersWaters Corporation stock faces uncertainty amid Trump national security alert and market volatility - AD HOC NEWSFierceBiotechIcon, Advarra partnership aims to optimize trials, expand accessAgilentAgilent Technologies Inc. stock rises on advanced chromatography solutions launch boosting lab effic - AD HOC NEWSLonza NewsLonza Group AG stock faces uncertainty amid board changes and biotech sector pressures in 2026 - AD HOC NEWSLonza NewsLonza Group AG stock faces pressure amid board changes ahead of 2026 annual meeting - AD HOC NEWS10x Genomics BlogVanguard amends 13G for 10X Genomics (NASDAQ: TXG) reporting 0 shares - Stock TitanCellPan-neurodegeneration proteomics reveals disease subtypes and molecular signaturesFierceBiotechMedtronic, Biotronik heart hardware make strides in conduction system pacingFierceBiotechGE HealthCare claims photon-counting CT clearance from FDACytiva (Google News)Cytiva-SR-TIGET Joint Venture Addresses Gene Therapy Bottlenecks - Inside Precision Medicine
Endpoints News Jan 6, 2026

J&J plans late-stage trial for lupus candidate after Phase 2 success

J&J plans late-stage trial for lupus candidate after Phase 2 success

Original
Body unavailable. Use the original source.

Directory

59 All